SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

How AI’s unseen revolution became a daily essential in just months

Social media’s double-edged sword: Israel’s war through the lens of Telegram and TikTok

Disillusionment from AI will lead to more productivity

Making Artificial Intelligence accessible to traditional institutions

Buzz

Most popular

Daily

Weekly

1

The next Wiz? Eon raises $77M at $750M valuation before product launch

2

How Intel's $108 billion buyback gambit backfired—a cautionary tale for tech giants

3

Nym raises $47 million for autonomous medical coding platform

4

Wiz, Kela, and the future of Israeli tech: How local startups continue to thrive against the odds

5

Pictet CEO: “Investors believe in Israeli tech”

Divestment

6 stories about Divestment

הפגנה מפגינים פיטורים טבע אשדוד

With No Buyers, Teva to Close Israeli Medical Equipment Plant

09.04.18|Dror Reich

The facility in Ashdod is one of five Teva intends to sell or close in its home country

Allergan to Sell Teva Shares to J.P. Morgan

14.11.17|Dror Reich and Lilach Baumer

Allergan announced it pledged its 9.8% stake in Teva to J.P. Morgan as collateral, as part of a loan agreement. The company already agreed to sell a quarter of the stock in the first quarter of 2018

מטה טבע פתח תקווה

Teva Offloads Holdings in Australia’s Mesoblast

25.10.17|Dror Reich and Lilach Baumer

The stem-cell therapy company diluted Teva’s shares through a new offering in August

Founding Family Sells Holdings in Online Gambling Company 888

09.10.17|Golan Hazani and Lilach Baumer

Co-founder Aaron Shaked’s heirs sold their entire stake for nearly $300 million

חברת ה תרופות טבע Teva

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer

After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal

מפעל חברת טבע הר חוצבים ירושלים

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer

CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday